BMO Capital Reiterates Outperform on Pfizer, Raises Price Target to $36
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Evan David Seigerman has reiterated an Outperform rating on Pfizer (NYSE:PFE) and increased the price target from $33 to $36.
May 02, 2024 | 2:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital has reiterated an Outperform rating on Pfizer and raised the price target from $33 to $36.
The reiteration of an Outperform rating combined with an increased price target suggests a positive outlook on Pfizer's stock by BMO Capital. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100